Document is current

Article History

Received: 13 July 2023

Accepted: 14 November 2023

First Online: 30 November 2023

Declarations

:

: This study was approved by the University of Leicester’s College of Life Sciences representatives (ref:14372) and the University of Salford’s Research Enterprise and Engagement ethical approval panel (ref:HSR1718-039). All participants provided written consent for participation.

: Not applicable.

: Authors declare support from the National Institute for Health and Care Research (NIHR) public health research programme, the Leicester Clinical Trials Unit, the NIHR Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre. MHG is a co-inventor of the activPAL3 physical activity monitor and a director of PAL Technologies. DWD reports grants from National Health and Medical Research Council (Australia), Diabetes Australia, and the National Heart Foundation of Australia, during the conduct of the study. GNH reports grants from the National Health and Medical Research Council (Australia) during the conduct of the study. MJD reports personal fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp and Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Servier, Mitsubishi Tanabe Pharma, and Takeda Pharmaceuticals International, and grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, and Janssen outside the submitted work.